ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Gross of the placeholder expense ratio and trading costs · not investor results
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1UNH | UNITEDHEALTH GROUP INC | Healthcare | $363.01B | 27.71% |
2MCK | MCKESSON CORP | Healthcare | $124.35B | 9.49% |
3CVS | CVS HEALTH CORP | Healthcare | $114.88B | 8.77% |
4ELV | ELEVANCE HEALTH INC | Healthcare | $92.88B | 7.09% |
5CI | CIGNA GROUP | Healthcare | $78.07B | 5.96% |
6COR | CENCORA INC | Healthcare | $66.67B | 5.09% |
7CAH | CARDINAL HEALTH INC | Healthcare | $64.29B | 4.91% |
8IDXX | IDEXX LABORATORIES INC | Healthcare | $54.99B | 4.20% |
9HUM | HUMANA INC | Healthcare | $53.29B | 4.07% |
10NTRA | NATERA INC | Healthcare | $46.83B | 3.57% |
11CNC | CENTENE CORP | Healthcare | $34.79B | 2.66% |
12GH | GUARDANT HEALTH INC | Healthcare | $20.95B | 1.60% |
13MEDP | MEDPACE HOLDINGS INC | Healthcare | $18.37B | 1.40% |
14BTSG | BRIGHTSPRING HEALTH SERVICES INC | Healthcare | $14.22B | 1.09% |
15UHS | UNIVERSAL HEALTH SERVICES INC | Healthcare | $11.18B | 0.85% |
16MOH | MOLINA HEALTHCARE INC | Healthcare | $10.95B | 0.84% |
17ENSG | ENSIGN GROUP INC | Healthcare | $10.88B | 0.83% |
18OSCR | OSCAR HEALTH INC | Healthcare | $9.92B | 0.76% |
19MDGL | MADRIGAL PHARMACEUTICALS INC | Healthcare | $9.88B | 0.75% |
20HSIC | HENRY SCHEIN INC | Healthcare | $9.52B | 0.73% |
21PACS | PACS GROUP INC | Healthcare | $7.62B | 0.58% |
22AXSM | AXSOME THERAPEUTICS INC | Healthcare | $7.59B | 0.58% |
23TWST | TWIST BIOSCIENCE CORP | Healthcare | $7.16B | 0.55% |
24CHE | CHEMED CORP | Healthcare | $7.16B | 0.55% |
25OPCH | OPTION CARE HEALTH INC | Healthcare | $4.75B | 0.36% |
26TARS | TARSUS PHARMACEUTICALS INC | Healthcare | $3.79B | 0.29% |
27WRBY | WARBY PARKER INC | Healthcare | $3.32B | 0.25% |
28GRDN | GUARDIAN PHARMACY SERVICES INC | Healthcare | $3.13B | 0.24% |
29PRVA | PRIVIA HEALTH GROUP INC | Healthcare | $3.02B | 0.23% |
30PGNY | PROGYNY INC | Healthcare | $2.69B | 0.21% |
31AVAH | AVEANNA HEALTHCARE HOLDINGS INC | Healthcare | $2.67B | 0.20% |
32ARDT | ARDENT HEALTH INC | Healthcare | $2.49B | 0.19% |
33MD | PEDIATRIX MEDICAL GROUP INC | Healthcare | $2.45B | 0.19% |
34UFPT | UFP TECHNOLOGIES INC | Healthcare | $2.37B | 0.18% |
35ADUS | ADDUS HOMECARE CORP | Healthcare | $2.31B | 0.18% |
36FTRE | FORTREA HOLDINGS INC | Healthcare | $1.94B | 0.15% |
37AGL | AGILON HEALTH INC | Healthcare | $1.85B | 0.14% |
38ASTH | ASTRANA HEALTH INC | Healthcare | $1.77B | 0.14% |
39INSP | INSPIRE MEDICAL SYSTEMS INC | Healthcare | $1.75B | 0.13% |
40HCSG | HEALTHCARE SERVICES GROUP INC | Healthcare | $1.69B | 0.13% |
41ALHC | ALIGNMENT HEALTHCARE INC | Healthcare | $1.57B | 0.12% |
42WGS | GENEDX HOLDINGS CORP | Healthcare | $1.55B | 0.12% |
43AMN | AMN HEALTHCARE SERVICES INC | Healthcare | $1.44B | 0.11% |
44PAHC | PHIBRO ANIMAL HEALTH CORP | Healthcare | $1.44B | 0.11% |
45NVCR | NOVOCURE LTD | Healthcare | $1.37B | 0.10% |
46PRCT | PROCEPT BIOROBOTICS CORP | Healthcare | $1.35B | 0.10% |
47URGN | UROGEN PHARMA LTD | Healthcare | $1.29B | 0.10% |
48INNV | INNOVAGE HOLDING CORP | Healthcare | $1.28B | 0.10% |
49PNTG | PENNANT GROUP INC | Healthcare | $1.26B | 0.10% |
50TNDM | TANDEM DIABETES CARE INC | Healthcare | $1.22B | 0.09% |
51ATEC | ALPHATEC HOLDINGS INC | Healthcare | $1.10B | 0.08% |
52SIBN | SI-BONE INC | Healthcare | $1.09B | 0.08% |
53CBLL | CERIBELL INC | Healthcare | $1.02B | 0.08% |
54BVS | BIOVENTUS INC | Healthcare | $915M | 0.07% |
55OMDA | OMADA HEALTH INC | Healthcare | $912M | 0.07% |
56SGHT | SIGHT SCIENCES INC | Healthcare | $611M | 0.05% |
57TCMD | TACTILE SYSTEMS TECHNOLOGY INC | Healthcare | $601M | 0.05% |
58NRC | NRC HEALTH | Healthcare | $565M | 0.04% |
59SENS | SENSEONICS HOLDINGS INC | Healthcare | $550M | 0.04% |
60MYGN | MYRIAD GENETICS INC | Healthcare | $545M | 0.04% |
61SRTA | STRATA CRITICAL MEDICAL INC | Healthcare | $515M | 0.04% |
62RCEL | AVITA MEDICAL INC | Healthcare | $509M | 0.04% |
63PHAT | PHATHOM PHARMACEUTICALS INC | Healthcare | $506M | 0.04% |
64ANGO | ANGIODYNAMICS INC | Healthcare | $504M | 0.04% |
65EOLS | EVOLUS INC | Healthcare | $475M | 0.04% |
66CARL | CARLSMED INC | Healthcare | $474M | 0.04% |
67NPCE | NEUROPACE INC | Healthcare | $413M | 0.03% |
68FENC | FENNEC PHARMACEUTICALS INC | Healthcare | $382M | 0.03% |
69TMCI | TREACE MEDICAL CONCEPTS INC | Healthcare | $350M | 0.03% |
70VMD | VIEMED HEALTHCARE INC | Healthcare | $345M | 0.03% |
71CV | CAPSOVISION INC | Healthcare | $314M | 0.02% |
72SMTI | SANARA MEDTECH INC | Healthcare | $299M | 0.02% |
73INFU | INFUSYSTEM HOLDINGS INC | Healthcare | $296M | 0.02% |
74OFIX | ORTHOFIX MEDICAL INC | Healthcare | $283M | 0.02% |
75PDEX | PRO DEX INC | Healthcare | $216M | 0.02% |
76ELMD | ELECTROMED INC | Healthcare | $204M | 0.02% |
77INGN | INOGEN INC | Healthcare | $146M | 0.01% |
78CUE | CUE BIOPHARMA INC | Healthcare | $127M | 0.01% |
79BDSX | BIODESIX INC | Healthcare | $109M | 0.01% |
80PARK | PARK DENTAL PARTNERS INC | Healthcare | $101M | 0.01% |
81JYNT | JOINT CORP | Healthcare | $92M | 0.01% |
82NRXS | NEURAXIS INC | Healthcare | $82M | 0.01% |
83ATRA | ATARA BIOTHERAPEUTICS INC | Healthcare | $81M | 0.01% |
84NTRB | NUTRIBAND INC | Healthcare | $73M | 0.01% |
85GOSS | GOSSAMER BIO INC | Healthcare | $69M | 0.01% |
86POCI | PRECISION OPTICS CORPORATION INC | Healthcare | $55M | 0.00% |
Full long-leg book as of November 2026 · cap-weighted · total market cap $1.31T. Hypothetical model holdings — not a registered fund’s portfolio.
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 465-name universe at November 2026. Rows: Large ≥ $4.2B, Small < $1.1B. Columns: Value ≥ 0.67, Growth < 0.36 B/M. The dot marks the capital-weighted centroid of the book — 97% toward Large, 47% toward Growth. +2% unclassified (12 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → November 2026; the right-hand end is the same value as the box’s dot. 86 names now. Hypothetical holdings — descriptive, not P&L.
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.
No more than 25% of total assets may be invested in the securities of any one issuer.
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
No verdict sits within 1.0pp of its limit.
Data version — panel=20261113T032607 rows=2198308 asof=202611 issuers=20261113T052248 rates=20261113T052248
Measured on the 2026-11 formation date across 86 holdings (cap-weighted). A different formation date can produce different verdicts.
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 335 monthly observations · about 3.4 in the 99% tail · paired percentile bootstrap over months
The estimators differ materially in value but agree on the verdict. Historical and Gaussian fund VaR differ by 25%; both still land on the same side of the 2x limit.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Did the edge survive the paper coming out?
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 18.1% | -10.0% |
| 3 yearsp.a. | 4.5% | -23.2% |
| 5 yearsp.a. | 5.1% | -3.3% |
| 10 yearsp.a. | 11.5% | -1.9% |
| Since inceptionp.a. | 12.2% | -1.3% |
| Year | Long leg | Long-short |
|---|---|---|
| 202611 mo | 21.0% | -8.9% |
| 2025 | 0.1% | -36.6% |
| 2024 | -7.9% | -8.2% |
| 2023 | 1.5% | -7.8% |
| 2022 | 0.6% | 47.8% |
| 2021 | 31.6% | 14.4% |
| 2020 | 19.9% | -26.1% |
| 2019 | 22.2% | -12.0% |
| 2018 | 8.8% | 36.2% |
| 2017 | 24.6% | 12.4% |
| 2016 | 1.5% | 39.0% |
| 2015 | 9.1% | 8.0% |
| 2014 | 30.4% | 7.6% |
| 2013 | 46.1% | -7.8% |
| 2012 | 12.5% | -16.3% |
| 2011 | 15.3% | -5.7% |
| 2010 | 16.2% | 9.4% |
| 2009 | 30.5% | 10.4% |
| 2008 | -42.1% | -41.6% |
| 2007 | 14.1% | 24.6% |
| 2006 | -0.2% | 11.1% |
| 2005 | 30.5% | 12.4% |
| 2004 | 26.5% | 19.8% |
| 2003 | 34.0% | -21.2% |
| 2002 | -0.5% | 75.1% |
| 2001 | -9.6% | -0.1% |
| 2000 | 100.7% | -23.1% |
| 1999 | -23.3% | -49.1% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through November 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
The Foundry Healthcare OPLev Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a OPLev signal and holds the top quintile with the highest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.